Occurrence and health risk assessment of pharmaceutical and personal care products (PPCPs) in tap water of Shanghai.
Abstract A monitoring study of 71 pharmaceuticals and personal care products (PPCPs) in tap water covered all districts of Shanghai. Nineteen PPCPs were detected in all samples, and most of them were detected with high concentration. Ten compounds were found with highest concentrations and their detection frequencies were over 80%, included thiamphenicol  (101.54 ng/L), florfenicol (84.56 ng/L), valsartan (66.84 ng/L), irbesartan (38.35 ng/L) hydrochlorothiazide (33.13 ng/L), 4-acetaminopyrine (48.16 ng/L), propylparaben (47.50 ng/L), dicyclohexylamine (42.33 ng/L), primidone (32.85 ng/L) and bisphenol A (31....
Source: Ecotoxicology and Environmental Safety - August 7, 2019 Category: Environmental Health Authors: Liu M, Yin H, Wu Q Tags: Ecotoxicol Environ Saf Source Type: research

Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension
AbstractBackgroundAngiotensin-converting enzyme inhibitors and calcium channel blockers in combination are widely recommended in hypertension guidelines. The advantages of single-pill combinations (SPCs) are increasingly recognized, so a dosage-adapted combination of perindopril and amlodipine was developed for the initial management of hypertension.ObjectiveThis randomized trial evaluated the blood pressure (BP)-lowering efficacy of four incremental doses of perindopril/amlodipine SPC in adults with mild-to-severe hypertension.MethodsEligible patients (N = 1617) were randomized to SPC perindopril 3.5 mg...
Source: American Journal of Cardiovascular Drugs - March 28, 2019 Category: Cardiology Source Type: research

Abdominal Septic shock: An Eye-Popping Case
Question: A 52-year-old Hingalese man was admitted to the emergency department for asthenia, dysuria, abdominal tenderness, chills, and fever of 10 days ’ duration. He has been living continuously in Italy for the last 5 years without family and has been working as a driver. He was previously in good health except for noninsulin-dependent diabetes mellitus and hypertension treated with irbesartan, hydrochlorothiazide, and metformin. The patient di d not smoke nor use drugs, but was a moderate to heavy drinker as reported by his friends. (Source: Gastroenterology)
Source: Gastroenterology - November 13, 2018 Category: Gastroenterology Authors: Tommaso Valobra, Umberto Ceratti, Anna Gandino Tags: Clinical Challenges and Images in GI Source Type: research

Efficacy Of Zofenopril Alone Or In Combination With Hydrochlorothiazide In Patients With Kidney Dysfunction.
Abstract Hypertension and kidney disease often coexist, further increasing the risk of future cardiovascular events. Treatment of hypertensive adults with an angiotensin converting enzyme inhibitor in case of concomitant kidney disease may slow disease progression. The third-generation liphophilic angiotensin converting enzyme inhibitor zofenopril, administered alone or combined with a thiazide diuretic, has proved to be effective in lowering blood pressure in hypertensive patients and to reduce the risk of fatal and non-fatal events in post-acute myocardial infarction and heart failure. In almost three-hundred hy...
Source: Current Clinical Pharmacology - October 25, 2018 Category: Drugs & Pharmacology Authors: Omboni S, Borghi C Tags: Curr Clin Pharmacol Source Type: research

Effect of Home Blood Pressure Monitoring on Patient ’s Awareness and Goal Attainment Under Antihypertensive Therapy: The Factors Influencing Results in Anti-HypertenSive Treatment (FIRST) Study
Conclusion: In a large Swiss cohort of patients with arterial hypertension, information and training on BP self-measurement and direct involvement of patients by using HBPM led to improvement in BP control. Treatment with irbesartan alone or in combination with hydrochlorothiazide was well tolerated and markedly reduced BP.Kidney Blood Press Res 2018;43:979 –986 (Source: Kidney and Blood Pressure Research)
Source: Kidney and Blood Pressure Research - June 25, 2018 Category: Urology & Nephrology Source Type: research

Cost-benefit effectiveness of angiotensin-II receptor blockers in patients with uncomplicated hypertension: A comparative analysis.
Abstract OBJECTIVE: The treatment of hypertensive patients (HTs) requires a long-term commitment of compliance for the patient and resources by the healthcare system. This poses an economic dilemma in countries where universal healthcare is standard. The aim of this study was to evaluate the costs/health benefit and effectiveness of treatment with angiotensin-II receptor blockers (ARBs) in uncomplicated essential hypertension. DESIGN AND METHODS: The daily and annual economic commitment for treating patients with ARBs was estimated using pharmacy dispensing records and the BP-lowering effects of candesartan, ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 14, 2017 Category: Drugs & Pharmacology Authors: Mazza A, Sacco AP, Townsend DM, Bregola G, Contatto E, Cappello I, Schiavon L, Ramazzina E, Rubello D Tags: Biomed Pharmacother Source Type: research

Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized “Z” Studies
AbstractCombinations between an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ) are among the recommended treatments for hypertensive patients uncontrolled by monotherapy. Four randomized, double-blind, parallel group studies with a similar design, including 1469 hypertensive patients uncontrolled by a previous monotherapy and with ≥1 cardiovascular risk factor, compared the efficacy of a combination of a sulfhydryl ACE inhibitor (zofenopril at 30 or 60 mg) or an ARB (irbesartan at 150 or 300 mg) plus HCTZ 12.5 mg. The extent of bloo...
Source: Advances in Therapy - March 4, 2017 Category: Drugs & Pharmacology Source Type: research

Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review
Publication date: Available online 10 February 2017 Source:The Lancet Author(s): Clara K Chow, Jay Thakkar, Alex Bennett, Graham Hillis, Michael Burke, Tim Usherwood, Kha Vo, Kris Rogers, Emily Atkins, Ruth Webster, Michael Chou, Hakim-Moulay Dehbi, Abdul Salam, Anushka Patel, Bruce Neal, David Peiris, Henry Krum, John Chalmers, Mark Nelson, Christopher M Reid, Mark Woodward, Sarah Hilmer, Simon Thom, Anthony Rodgers Background Globally, most patients with hypertension are treated with monotherapy, and control rates are poor because monotherapy only reduces blood pressure by around 9/5 mm Hg on average. There is a pressin...
Source: The Lancet - February 11, 2017 Category: Journals (General) Source Type: research

Drug-Drug Multicomponent Solid Forms: Cocrystal, Coamorphous and Eutectic of Three Poorly Soluble Antihypertensive Drugs Using Mechanochemical Approach.
Abstract The present study deals with the application of mechanochemical approach for the preparation of drug-drug multicomponent solid forms of three poorly soluble antihypertensive drugs (telmisartan, irbesartan and hydrochlorothiazide) using atenolol as a coformer. The resultant solid forms comprise of cocrystal (telmisartan-atenolol), coamorphous (irbesartan-atenolol) and eutectic (hydrochlorothiazide-atenolol). The study emphasizes that solid-state transformation of drug molecules into new forms is a result of the change in structural patterns, diminishing of dimers and creating new facile hydrogen bonding ne...
Source: AAPS PharmSciTech - January 18, 2017 Category: Drugs & Pharmacology Authors: Haneef J, Chadha R Tags: AAPS PharmSciTech Source Type: research

Copeptin is increased in resistant hypertension
Objectives: The participation of vasopressin in the mechanisms of resistant hypertension is unclear. We compared plasma copeptin concentration, a surrogate marker for vasopressin secretion, between patients with resistant hypertension and those with controlled blood pressure (CBP), in a post hoc analysis of the Prise en charge de l’Hypertension Artérielle RESistante au traitement trial. Methods: After 4-week treatment with irbesartan 300 mg/day, hydrochlorothiazide 12.5 mg/day, and amlodipine 5 mg/day (baseline), 166 patients were classified as having resistant hypertension (n = 140) or CBP (n =...
Source: Journal of Hypertension - November 4, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Resistant hypertension Source Type: research

Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome)
Objective: Whether all antihypertensive drugs are equally effective in patients with metabolic syndrome is still unclear. The goal of the Zofenopril in Advanced MEtabolic Syndrome (ZAMES) study was to investigate whether treatment with the fixed-dose combination of sulphydril-containing angiotensin-converting enzyme inhibitor zofenopril plus hydrochlorothiazide is at least as effective as that with the angiotensin receptor blocker irbesartan plus hydrochlorothiazide in patients with metabolic syndrome and essential hypertension, uncontrolled by a previous monotherapy. Methods: We enrolled 721 patients in a multicenter, in...
Source: Journal of Hypertension - September 30, 2016 Category: Cardiology Tags: Original Article: Therapeutic aspects Source Type: research

Byvalson - A Beta Blocker/ARB Combination for Hypertension
Date: September 12, 2016 Issue #:  1503Summary:  The FDA has approvedByvalson (Allergan), a fixed-dose combination of the beta blocker nebivolol(Bystolic) and the angiotensin receptor blocker (ARB) valsartan (Diovan, and generics), for treatment of hypertension. It is the only combination product that contains nebivolol, and the first to combine a beta blocker with an ARB. (Source: The Medical Letter)
Source: The Medical Letter - August 24, 2016 Category: Drugs & Pharmacology Authors: admin Tags: ACE inhibitors Amlodipine Angiotensin receptor blockers Atacand Atenolol Avalide azilsartan Azor Bendroflumethiazide Benicar Beta blockers Bisoprolol Bystolic Byvalson Chlorthalidone Corzide Diovan Diuretics Edarbyclor Source Type: research

Zofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized study
Objective: To compare zofenopril + hydrochlorothiazide (Z + H) vs. irbesartan + hydrochlorothiazide (I + H) efficacy on daytime SBP in elderly (>65 years) patients with isolated systolic hypertension (ISH), untreated or uncontrolled by a previous monotherapy. Methods: After a 1-week run-in, 230 ISH patients (office SBP ≥ 140 mmHg and DBP  (Source: Journal of Hypertension)
Source: Journal of Hypertension - January 30, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

RP-HPLC Stability-indicating Method for Estimation of Irbesartan and Hydrochlorothiazide in Bulk and Pharmaceutical Dosage Form
In this study, hydrochlorothiazide and irbesartan were degraded under different stress test conditions as recommended by the International Conference on Harmonization (ICH). The degraded samples were used to develop a stability indicating high performance liquid chromatographic method (HPLC) for hydrochlorothiazide and irbesartan determination. The two drugs were separated from their degradation products using a reversed phase (C18) analytical column and a mobile phase consisted of 50 mM potassium di-hydrogen orthophosphate:acetonitrile (55:45, V/V) buffer (pH 2.5). The instrumental settings were optimized at flow rate of ...
Source: Chinese Journal of Analytical Chemistry - January 27, 2016 Category: Chemistry Source Type: research

Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial.
In conclusion, uncontrolled monotherapy treated hypertensives effectively respond to a combination of zofenopril or irbesartan plus a thiazide diuretic, in terms of either BP response or target organ damage progression. PMID: 26347187 [PubMed] (Source: International Journal of Hypertension)
Source: International Journal of Hypertension - September 11, 2015 Category: Cardiology Tags: Int J Hypertens Source Type: research

Pharmacokinetic properties and bioequivalence of two irbesartan/ hydrochlorothiazide fixed-dose combination tablets in healthy male Chinese volunteers.
CONCLUSION: In this study, a single dose (300/12.5-mg) of the test formulation of irbesartan and hydrochlorothiazide FDC tablet in fasting healthy Chinese male volunteers met WHO's and China's FDA regulatory criteria for assumption of bioequivalence to the reference formulation based on AUC and Cmax. Both formulations were well tolerated. PMID: 25828636 [PubMed - as supplied by publisher] (Source: International Journal of Clinical Pharmacology and Therapeutics)
Source: International Journal of Clinical Pharmacology and Therapeutics - June 4, 2015 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

The effects of a low-salt diet on the efficacy of different antihypertensive drug regimens.
The objective of this study was to compare the antihypertensive effects of 3 types of antihypertensive drug regimens between different salt intake levels. The 180 patients with mild to moderate primary hypertension participating in this randomized controlled clinical trial were randomly allocated to a low-salt diet (LSD) group or a non-low-salt diet (NLSD) group. Each group included three subgroups: a losartan 100 mg subgroup, a losartan 50 mg/hydrochlorothiazide (HCTZ) 12.5 mg subgroup, and an irbesartan 150 mg/HCTZ 12.5 mg subgroup. The LSD group received a diet in which the sodium content was strictly controlled (2.3 g/...
Source: The Journal of Clinical Pharmacology - June 4, 2015 Category: Drugs & Pharmacology Authors: Zhuang J, Qiu B, Du JL, Deng SB, Liu YJ, She Q Tags: J Clin Pharmacol Source Type: research

Seasonal distribution of pharmaceuticals in marine water and sediment from a mediterranean coastal lagoon (SE Spain).
D, León VM Abstract The seasonal variations in the occurrence and distribution of pharmaceuticals were evaluated in seawater and sediment of Mar Menor lagoon from spring 2010 to winter 2011. A total of 20 pharmaceuticals in seawater and 14 in sediments were found at concentrations from low ngL(-)(1) up to 168ngL(-)(1) (azithromycin) in seawater and from low ngg(-1) up to 50.3ngg(-1) (xylazine) in sediments. Azithromycin, xylazine and metoprolol were the most ubiquitous compounds in seawater since they were found in all seawater samples collected. Seven compounds were quantified in both matrices: clarithromy...
Source: Environmental Research - March 9, 2015 Category: Environmental Health Authors: Moreno-González R, Rodriguez-Mozaz S, Gros M, Barceló D, León VM Tags: Environ Res Source Type: research

Modeling of the pharmacokinetic/pharmacodynamic interaction between irbesartan and hydrochlorothiazide in normotensive subjects
ConclusionA limited potential for clinically significant interactions between IRB and HCT at the given doses were observed; therefore, no dosage adjustments were recommended for either drug when used together. This article is protected by copyright. All rights reserved. (Source: Biopharmaceutics and Drug Disposition)
Source: Biopharmaceutics and Drug Disposition - December 27, 2014 Category: Drugs & Pharmacology Authors: Mohsen A. Hedaya, Sally A. Helmy Tags: Original Paper Source Type: research

HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets.
Abstract Abstract A simple, sensitive and accurate HPLC method with high throughput has been developed and validated for the simultaneous determination of irbesartan (IRB) and hydrochlorothiazide (HCT) in combined pharmaceutical dosage forms. The proposed method employed, for the first time, a monolithic column in the analysis. Optimal chromatographic separation of the analytes was achieved on Chromolith® Performance RP-18e column using a mobile phase consisting of phosphate buffer (pH 4)/acetonitrile (50:50, V/V) pumped isocratically at a flow rate of 1.0 mL min-1. The eluted analytes were monitored with a UV...
Source: Acta Pharmaceutica - June 1, 2014 Category: Drugs & Pharmacology Authors: Alanazi AM, Abdelhameed AS, Khalil NY, Khan AA, Darwish IA Tags: Acta Pharm Source Type: research

Zofenopril Plus Hydrochlorothiazide and Irbesartan Plus Hydrochlorothiazide in Previously Treated and Uncontrolled Diabetic and Non-diabetic Essential Hypertensive Patients.
CONCLUSION: In previously monotherapy-treated, uncontrolled patients with hypertension, zofenopril 30-60 mg + HCTZ 12.5 mg is as effective as irbesartan 150-300 mg plus HCTZ 12.5 mg, with the added value of a potential protective effect against vascular inflammation. PMID: 24415271 [PubMed - as supplied by publisher] (Source: Advances in Therapy)
Source: Advances in Therapy - January 11, 2014 Category: Drugs & Pharmacology Authors: Agabiti-Rosei E, Manolis A, Zava D, Omboni S Tags: Adv Ther Source Type: research

Reversible stroke-like symptoms with severe hyponatremia.
Abstract A 65-year-old Caucasian female was brought to the Emergency Department by her husband for increasing generalized weakness, slurred speech and new-onset facial droop. A non-contrast computerized tomography scan of her brain was negative; however, she was found to have a sodium level of 99 mmol/L. Her daily medications included hydrochlorothiazide, omeprazole and irbesartan. On physical examination, she was found to have slight confusion, lethargy, slowed speech, generalized weakness and left-sided facial droop but no other focal deficits. Over the course of her hospital stay, the patient's sodium levels we...
Source: Tennessee Medicine - February 1, 2013 Category: Internal Medicine Authors: Holloman LN, Kolade VO, Zapko DR, Youngblood LB Tags: Tenn Med Source Type: research

The Role of ARBs Alone or with HCTZ in the Treatment of Hypertension and Prevention of Cardiovascular and Renal Complications
Conclusions: Early use of ARB/HCTZ combination therapy achieves critical decrease in BP and is an effective treatment for patients with moderate to severe HTN. Angiotensin receptor blockers also have renal- and CV-protective properties in conjunction with their antihypertensive effects, providing additional benefit to patients who at risk of vascular disease. Keywords: hypertension; renal protection; angiotensin II receptor blocking agents; ARBs; cardiovascular read more (Source: Postgraduate Medicine Online)
Source: Postgraduate Medicine Online - March 19, 2012 Category: Internal Medicine Authors: admin Source Type: research